Novo Nordisk is the world's leading biopharmaceutical company. It is a world leader in the development and production of insulin for the treatment of diabetes. The customer wanted to adjust the sales model by changing the paid purchase of insulin pens to free access. This marketing method places great demand on the iteration and upgrade of the insulin pen to maintain its leading position in technology. In addition, Novo wants the saving of the overall cost to complete the adjustment of the sales model and promote insulin sales.
Novo Nordisk is the world's leading biopharmaceutical company. It is a world leader in the development and production of insulin for the treatment of diabetes. The customer wanted to adjust the sales model by changing the paid purchase of insulin pens to free access. This marketing method places great demand on the iteration and upgrade of the insulin pen to maintain its leading position in technology. In addition, Novo wants the saving of the overall cost to complete the adjustment of the sales model and promote insulin sales.
1. Inherit product genes - Novo Nordisk secures a leading position in product technology development and production and thus is quite demanding on the continuity of its brand. It requires not only the iteration and upgrade of the product but also the continuity of the previous generation product genes in terms of the overall appearance of the insulin pen. With little to change (the continuity of the outer contour arc, the design element reminder on how to use and open, and the rotary calibration cap), LKKER SCM conducted upgrade of all other parts and redesigned the dial to jut out 1mm to prevent slipping when placing the pens, which were highly praised by Novo Nordisk.
2. Operated the section every five seconds to deliver the most detailed use study. Conducted operation process comparison and analysis of Novo3 and Novo4 and performed section shooting, disassembly and detail analysis every five seconds to simplify the use, optimize the shape, and reduce the irritability or fear of the patient during use.
The design project of the Novo Nordisk insulin pen was bidding globally and proposed in Denmark. LKKER SCM defeated a number of international rivals including FROG and B&O and won the customer's recognition. We iteratively upgraded the insulin pen while inheriting the system gene, simplified the way of use, improved the human-machine experience, maximized the brand effect of the healthcare product and achieved the goal of changing the sales model.
We use cookies to ensure that we give you the best experience on our website. By clicking "Accept All", you consent to our use of cookies. Learn more.
Please fill out the form and we'll get back to you shortly.
Enter your details to receive the toolkit for free.
